Source: GlobalData
US structural heart occlusion market sees early 2025 growth amid trade uncertainty, says GlobalData
Posted in Medical Devices
The US Structural Heart Occlusion (SHO) market posted a notable 39% year-over-year revenue increase in Q1 2025, amid heightened trade policy uncertainty following President Donald Trump’s re-election and the swift introduction of new tariff measures in early 2025, according to GlobalData, a leading data and analytics company.
Trump’s new tariff regime includes a 10% global baseline and a “reciprocal” tariff framework that has unsettled global trade norms. With broad tariffs on strategic sectors and a 90-day pause on some reciprocal tariffs, businesses and healthcare providers are facing a shifting economic landscape.
According to data from GlobalData’s panel of medical facilities, March 2025 revenue growth in the SHO market grew over 50% compared to March 2024, signaling a late-quarter surge in demand.
Thomas Fleming, Medical Analyst at GlobalData, comments: “The surge in growth may be less about increased patient demand and more about precautionary stockpiling. Hospitals appear to be accelerating procurement of high-value medical devices—such as those used for structural heart occlusion—in anticipation of rising costs and supply disruptions. This response reflects growing concerns about the sustainability of supply chains and the potential financial impact of extended tariff enforcement.”
Fleming continues: “Historically, the US has held a leadership role in the global SHO market, driven by high incidence rates of structural heart conditions and robust innovation in cardiac care. However, the current environment marks a sharp contrast with previous expectations of stable, predictable growth. With global supply chains in flux and trade negotiations still unsettled, market stakeholders are left navigating increased risk.”
Fleming concludes: “While Q1’s growth may appear encouraging at first glance, it underscores the reactive measures health systems are taking in an uncertain policy environment. The long-term effects of these tariffs on device pricing, research investments, and patient outcomes remain to be seen, leaving the sector in a state of cautious watchfulness.”